Remove special-reports
article thumbnail

'The Top Line': A look at pharma revenue rankings

Fierce Pharma

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Staff Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report.

52
article thumbnail

U.S. must address IP and market access barriers abroad to protect American innovation

PhRMA

Trade Representative (USTR)’s 2023 Special 301 Report. PhRMA recently submitted comments to the Office of the U.S. The comments highlight foreign government actions and policies that undermine American innovation, biopharmaceutical leadership and more than 4.4 million American jobs.

185
185
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

'The Top Line': Fiercest Women in Life Sciences, meet the Fierce 50

Fierce Pharma

In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. | In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report.

105
105
article thumbnail

Quitting alcohol — or even drinking less — reduces risk of oral cavity and esophageal cancer, per new analysis

STAT

Reducing or eliminating alcohol consumption reduces the risk of developing oral cavity and esophagus cancers, according to a special report from the International Agency for Research on Cancer. But more data are needed to conclude whether the same is true for several other cancer types, including colorectal, breast, and liver cancer.

145
145
article thumbnail

'The Top Line': A closer look at the bounty of new drug approvals in 2023

Fierce Pharma

At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. | At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals.

52
article thumbnail

STAT+: Key takeaways from AdvaMed, the world’s largest medical device conference

STAT

In its annual medtech report , EY reported a 30% decline in all industry financing, which includes a drop in initial public offerings, special-purpose acquisition company deals, and venture capital funding. Continue to STAT+ to read the full story…

FDA 124
article thumbnail

The highs — and lows — of JPM 2024 you should pay attention to

STAT

In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference,  join our newsletter list.

FDA 107